# Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

> **NCT01789281** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Sandostatin LAR Depot

## Key facts

- **NCT ID:** NCT01789281
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-14
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01789281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01789281, "Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01789281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*